If you’ve been looking for a sector that combines steady demand, innovation, and long-term growth potential, healthcare is hard to beat. Whether markets are booming or stumbling, people still need medicine, surgery, and insurance — and that makes the best healthcare stocks to buy in 2026 a compelling opportunity for investors at every level.
Global healthcare spending is on an upward trajectory throughout this decade. Aging populations, the rise of obesity treatments, breakthroughs in cancer care, robotic surgery, and artificial intelligence in diagnostics are all reshaping the industry. That creates opportunities across pharmaceuticals, medical devices, insurance companies, hospitals, and distribution networks.
In this article, we count down the 10 best healthcare stocks to buy in 2026 — from a high-risk high-reward pick at #10 all the way to the dominant growth engine sitting at #1. We’ll cover the bull case, the main risk, and who each stock is best suited for.
Let’s get into it.
What Makes a Great Healthcare Stock in 2026?
Before we count down the list, it’s worth understanding what separates a good healthcare investment from a great one. The best healthcare stocks in 2026 share several common traits:
- They serve growing, non-discretionary demand (people don’t stop needing healthcare when times get tough)
- They have defensible competitive advantages — patents, FDA approvals, or high switching costs
- They generate strong and consistent cash flows
- They are positioned in at least one high-growth theme: obesity drugs, oncology, robotics, biotech, or AI in healthcare
If you want to understand how healthcare stocks fit within a broader US equity portfolio, check out our guide on the
If you want to understand how healthcare stocks fit within a broader US equity portfolio, check out our guide on the top 30 S&P 500 stocks to buy — many of these healthcare names are already index heavyweights.
💡 Want to invest in these U.S. stocks from anywhere in the world?
GoTrade lets you buy fractional shares of U.S.-listed stocks with no minimum investment. It’s built for beginners, supports global investors, and makes it simple to start building a portfolio in international markets directly from your phone.
The 10 Best Healthcare Stocks to Buy in 2026
#10. TransMedics Group (TMDX) — The High-Risk Moonshot
Kicking off our list is TransMedics Group, a smaller company with an outsized opportunity. TransMedics developed the Organ Care System (OCS), a technology that keeps donor organs alive and functional outside the body for significantly longer than traditional cold-storage methods. This extends the transplant window, potentially saving more lives and dramatically increasing the addressable transplant market.
The bull case here is simple: organ transplantation is a massive and underserved market, and TransMedics has a first-mover advantage in an area where clinical outcomes genuinely matter. If adoption continues accelerating — both in the US and internationally — growth could remain substantial for years.
The main risk is equally clear. TransMedics is a smaller company, which means it carries higher volatility, greater execution risk, and less financial cushion than the giants on this list.
Best For: Aggressive growth investors comfortable with higher volatility.
#9. Cardinal Health (CAH) — The Defensive Workhorse
Cardinal Health doesn’t generate the headlines that pharmaceutical stocks do, but it plays an essential role in the US healthcare system as one of the largest pharmaceutical distributors in the country. Without companies like Cardinal Health, hospitals and pharmacies wouldn’t reliably receive the medications and supplies they depend on.
That makes Cardinal Health one of the most defensive healthcare stocks on this list. It generates reliable cash flows, benefits from secular growth in healthcare spending, and offers income-focused investors a relatively stable holding even during market turbulence.
The trade-off is that distribution margins are thin, and the business faces ongoing competition within the supply-chain segment. This is not a stock you buy for explosive growth — it’s a stock you buy for ballast.
Best For: Income and value investors seeking a defensive healthcare allocation.
#8. HCA Healthcare (HCA) — The Hospital Giant
HCA Healthcare is one of the largest for-profit hospital operators in the United States, with a network that spans dozens of states and hundreds of facilities. As healthcare utilization grows — driven by an aging US population and increasing procedure volumes — HCA is well-positioned to capture that demand.
The operational leverage in HCA’s model is a key attraction. Once the fixed infrastructure is in place, each additional procedure adds high-margin revenue. Consistent cash flow generation allows the company to invest in technology, expand facilities, and return capital to shareholders.
Labor costs and reimbursement pressures remain the primary risks. Healthcare workers are in high demand, which keeps wages elevated, and any shifts in Medicare or Medicaid reimbursement rates can directly impact profitability.
Best For: Investors seeking healthcare-services exposure with strong operating cash flow.
#7. Intuitive Surgical (ISRG) — The Robotics Leader
Intuitive Surgical sits at the intersection of two powerful investment themes: medical technology and robotics. The company’s da Vinci surgical system is the global leader in robotic-assisted surgery, used by hospitals worldwide for minimally invasive procedures that result in faster patient recovery times and lower complication rates.
What makes Intuitive Surgical particularly compelling is its business model. Hospitals that install da Vinci systems face significant switching costs — surgeons are trained on the platform, workflows are built around it, and patients expect it. That creates durable competitive advantages and a recurring revenue stream from instruments and services.
The valuation is not cheap. Intuitive Surgical consistently trades at a premium, which means any stumble in procedure growth or hospital spending could create meaningful downside. But for investors with a five-to-ten-year horizon, the robotics adoption story still has considerable runway.
Best For: Long-term growth investors with tolerance for premium valuations.
#6. Vertex Pharmaceuticals (VRTX) — The High-Quality Biotech
Vertex Pharmaceuticals stands out in the biotechnology sector because it has achieved something rare: it’s both innovative and consistently profitable. The company built its foundation on cystic fibrosis (CF) treatments, and its Trikafta therapy revolutionized outcomes for CF patients worldwide.
But here’s what makes Vertex especially exciting heading into 2026 — it’s no longer a one-disease company. Vertex has expanded aggressively into gene editing therapies, pain management treatments, and kidney disease, creating a pipeline that could sustain growth well beyond its CF franchise.
The primary risk remains concentration in cystic fibrosis revenue in the near term, but the balance sheet is strong and the pipeline is arguably one of the best in biotechnology.
Best For: Investors who want biotech exposure with lower risk than a typical early-stage biotech.
Curious how to build broader exposure to US innovation stocks? Our guide on how to invest in the Nasdaq 100 walks you through the options for investors who want index-level access to the best US growth companies.
#5. Merck & Co. (MRK) — The Oncology Powerhouse
Merck & Co. makes our list of the best healthcare stocks to buy in 2026 because of one extraordinary product: Keytruda. This immunotherapy drug has become one of the best-selling cancer treatments in the world, approved across dozens of cancer indications and continuing to generate billions in annual revenue.
Beyond Keytruda, Merck maintains a healthy pipeline, solid cash flows, and a valuation that — especially compared to peers like Eli Lilly — looks reasonable. That combination of growth and value is genuinely attractive in a sector where many top stocks trade at lofty multiples.
The main risk is long-term. Keytruda faces patent headwinds further down the decade, which means Merck’s pipeline execution will need to deliver meaningful new products to sustain growth momentum.
Best For: Balanced investors who want oncology exposure with reasonable valuation.
#4. AbbVie (ABBV) — The Dividend Growth Machine
AbbVie went through a genuine test over the past few years as sales of its blockbuster drug Humira — once the world’s best-selling medicine — declined following the loss of US patent exclusivity. But AbbVie navigated that cliff successfully, with newer immunology drugs Skyrizi and Rinvoq stepping up as major revenue drivers.
That’s a remarkable execution story, and it’s one of the reasons AbbVie continues to attract income-focused investors. The company offers an attractive dividend yield, a growing earnings outlook, and a diversified immunology franchise that remains difficult to compete against.
The risk here is concentration — AbbVie’s pipeline success depends heavily on a relatively small number of key products. But the transition from Humira dependency has already been largely accomplished, which reduces near-term execution risk.
Best For: Dividend-growth investors seeking income from a healthcare blue chip.
#3. Johnson & Johnson (JNJ) — The Bedrock Holding
Johnson & Johnson is as close to a “sleep well at night” healthcare stock as you’ll find in the US market. The company operates across pharmaceuticals and medical technology, maintaining diversified revenue streams that reduce the impact of any single product failure or regulatory setback.
JNJ has a long history of dividend growth, a rock-solid balance sheet, and the scale to invest heavily in R&D while simultaneously returning capital to shareholders. It’s not the fastest grower on this list, but for conservative investors who want reliable healthcare exposure, it is hard to argue against.
The trade-off is exactly that — slower growth. If you’re looking for outsized returns, other names on this list may be more appropriate. But if you want stability and income, JNJ delivers.
Best For: Conservative investors seeking stability, income, and long-term capital preservation.
#2. UnitedHealth Group (UNH) — The Healthcare Ecosystem
UnitedHealth Group is not just an insurer — it’s arguably the most comprehensive healthcare ecosystem in the United States. Through its insurance operations and its Optum healthcare-services platform, UnitedHealth touches virtually every part of the healthcare system: insurance coverage, pharmacy benefits, data analytics, and direct care delivery.
That scale creates significant competitive advantages. UnitedHealth’s cost efficiency, data capabilities, and integrated model are extremely difficult for smaller competitors to replicate. The company also generates strong, consistent cash flows that fund both growth investments and capital returns.
The risks are real: Medicare Advantage reimbursement pressure and regulatory scrutiny are ongoing concerns. But for investors who want core healthcare exposure in a single stock, UnitedHealth is the benchmark holding.
Best For: Core portfolio investors seeking large-cap, diversified healthcare exposure.
#1. Eli Lilly (LLY) — The Undisputed Growth Engine
The top spot on our list of the best healthcare stocks to buy in 2026 belongs to Eli Lilly, and it’s not particularly close. Eli Lilly has transformed itself into the dominant player in one of the most commercially significant drug categories in pharmaceutical history: obesity and diabetes treatment through GLP-1 medications.
Mounjaro and Zepbound have become blockbuster products almost immediately after launch, generating some of the fastest revenue growth ever seen in the pharmaceutical industry. But here’s the real opportunity — obesity treatment is still in its early innings. Hundreds of millions of people globally could benefit from GLP-1 therapies, and Eli Lilly is leading the charge in bringing them to market.
Beyond obesity, Eli Lilly’s pipeline extends into Alzheimer’s disease, immunology, and cancer — meaning the growth story does not depend entirely on the obesity franchise even if competition intensifies.
The main risk is valuation: Eli Lilly is priced as a premium growth stock, and any execution misstep or competitive development could trigger significant downside. This is not a stock you buy for value — you buy it for growth.
Best For: Growth investors with a multi-year horizon and comfort with higher valuations.
Quick Comparison: 10 Best Healthcare Stocks to Buy in 2026
| Stock | Ticker | Style | Key Theme | Risk Level |
|---|---|---|---|---|
| Eli Lilly | LLY | Growth | Obesity / GLP-1 drugs | Medium-High |
| UnitedHealth | UNH | Core | Insurance + services | Medium |
| Johnson & Johnson | JNJ | Conservative | Pharma + MedTech | Low |
| AbbVie | ABBV | Dividend | Immunology drugs | Medium |
| Merck & Co. | MRK | Balanced | Oncology (Keytruda) | Medium |
| Vertex Pharma | VRTX | Core/Biotech | Cystic fibrosis + pipeline | Medium |
| Intuitive Surgical | ISRG | Growth | Robotic surgery | Medium-High |
| HCA Healthcare | HCA | Services | Hospital operations | Medium |
| Cardinal Health | CAH | Income/Value | Supply chain / distribution | Low-Medium |
| TransMedics | TMDX | Aggressive | Organ transplant tech | High |
Best Healthcare Stocks by Investment Style
| Investment Style | Best Stocks |
|---|---|
| Dividend Income | AbbVie (ABBV), Johnson & Johnson (JNJ), Cardinal Health (CAH) |
| Defensive / Conservative | Johnson & Johnson (JNJ), Merck (MRK), Cardinal Health (CAH) |
| Core Holdings | UnitedHealth (UNH), Merck (MRK), Vertex Pharmaceuticals (VRTX) |
| Growth | Eli Lilly (LLY), Intuitive Surgical (ISRG), Vertex (VRTX) |
| Aggressive Growth | Eli Lilly (LLY), Intuitive Surgical (ISRG), TransMedics (TMDX) |
A Simple 5-Stock Healthcare Portfolio for 2026
If you want diversified healthcare exposure without holding all ten names, consider building around these five positions:
- Eli Lilly (LLY) — Growth engine and GLP-1 leader
- UnitedHealth Group (UNH) — Healthcare ecosystem and core holding
- Merck & Co. (MRK) — Oncology powerhouse at a reasonable valuation
- Vertex Pharmaceuticals (VRTX) — High-quality biotech with a diversifying pipeline
- Intuitive Surgical (ISRG) — Long-term robotics leader with recurring revenue
This combination gives you exposure to obesity drugs, healthcare services, oncology, biotechnology, and surgical robotics — five of the strongest investment themes in healthcare today.
If you’re building a broader US stock portfolio alongside your healthcare picks, our guide to the S&P 500 explains how the index works and why it remains the foundation of most long-term investment strategies.
🏥 Ready to buy your first U.S. healthcare stocks?
GoTrade makes it easy to invest in leading U.S.-listed healthcare companies like Eli Lilly, Merck, and UnitedHealth — even with a small starting amount. No complicated setup, no minimum investment, and fractional shares make it accessible for beginners worldwide.
Frequently Asked Questions: Best Healthcare Stocks to Buy in 2026
1. What are the best healthcare stocks to buy in 2026?
The top picks for 2026 include Eli Lilly, UnitedHealth Group, Merck & Co., Vertex Pharmaceuticals, and Intuitive Surgical, among others. The best choice depends on your investment style — growth, income, or stability.
2. Is healthcare a good sector to invest in right now?
Yes. Healthcare is considered a defensive and growth-oriented sector simultaneously. Aging populations, medical innovation, and rising global health spending make it a compelling long-term investment regardless of broader market conditions.
3. What is a GLP-1 drug and why does it matter for investors?
GLP-1 drugs are a class of medications originally developed for diabetes that have proven remarkably effective for weight loss. Companies like Eli Lilly have seen explosive revenue growth from these treatments, and the market is expected to remain large for years.
4. Are healthcare stocks safe for beginners?
Large-cap healthcare stocks like Johnson & Johnson, Merck, and UnitedHealth are generally considered lower-risk compared to early-stage biotechs. They provide stability and in some cases dividends, making them suitable for beginner investors building a core portfolio.
5. How do I invest in US healthcare stocks as an international investor?
Platforms like GoTrade allow investors from multiple countries to buy fractional shares of US-listed stocks, including all the companies on this list. You don’t need a large starting capital to begin.
6. What is the difference between pharma stocks and biotech stocks?
Pharmaceutical companies like Merck and Eli Lilly are typically large, established businesses with diversified revenue and approved products. Biotech companies like Vertex often rely more heavily on a smaller number of drugs or a research pipeline, which creates both higher potential rewards and higher risk.
7. Is Eli Lilly stock overvalued?
Eli Lilly trades at a premium valuation reflecting its leadership in GLP-1 obesity drugs and strong growth outlook. Whether it’s “overvalued” depends on how the obesity drug market develops — if growth continues, the premium may be justified. If competition intensifies faster than expected, the stock could face pressure.
8. What makes Intuitive Surgical a good long-term investment?
Intuitive Surgical benefits from high switching costs, a recurring revenue model from instrument and service contracts, and a long runway for global robotic surgery adoption. Hospitals that adopt da Vinci systems tend to stay on the platform, creating durable competitive advantages.
9. Should I buy individual healthcare stocks or a healthcare ETF?
Individual stocks offer higher potential returns but require more research and carry company-specific risk. A healthcare ETF provides instant diversification across the sector. Many investors combine both — using ETFs as a base and adding individual stocks for targeted exposure.
10. How many healthcare stocks should I hold in my portfolio?
Most financial professionals suggest holding three to seven stocks within a sector to maintain diversification without over-diversification. A five-stock portfolio covering different healthcare sub-sectors — pharma, insurance, biotech, medical devices, and services — is a practical starting point.
Conclusion: Building Your Healthcare Stock Portfolio in 2026
Healthcare is one of the few sectors that combines defensive stability with genuine innovation-driven growth — and that makes it worth a serious look for long-term investors in 2026.
The 10 best healthcare stocks to buy in 2026 span the full range of investment styles. Whether you’re a conservative investor drawn to Johnson & Johnson’s dividend history, a growth investor excited about Eli Lilly’s obesity drug franchise, or someone looking for biotech exposure through Vertex Pharmaceuticals, this list gives you a starting point for building a diversified healthcare portfolio.
The key is matching the stocks you choose to your personal risk tolerance, investment timeline, and financial goals. No single stock is right for every investor — but a well-constructed healthcare allocation could serve your portfolio well for years to come.
🚀 Start investing in U.S. healthcare stocks today
GoTrade is one of the easiest ways for investors outside the U.S. to access American markets. Buy fractional shares of companies like Eli Lilly, UnitedHealth, Merck, and more — starting with small amounts and without needing a large account balance. It’s a simple, beginner-friendly way to start building a global portfolio.